Showing results (331-340 of 387) with videos related to

Sort By:
Pageof 39
Biorxiv : the Preprint Server for Biology|November 24, 2025
Stabilized Full-Length Measles Fusion Protein Elicits Potent Immunity and Protection In VivoDawid S Zyla, Gillian Zipursky, Roberta Della Marca, et al.
Genome Research|June 6, 2014
A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samplesSamia N Naccache, Scot Federman, Narayanan Veeraraghavan, et al.
Emerging Infectious Diseases|September 23, 2022
Human Parainfluenza Virus in Homeless Shelters before and during the COVID-19 Pandemic, Washington, USAEric J Chow, Amanda M Casto, Reigran Sampoleo, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish Choudhary, et al.
Nature Communications|April 6, 2026
Structural and mechanistic basis for antibody neutralization of the measles fusion proteinDawid S Zyla, Roberta Della Marca, Davide Lacarbonara, et al.
Cell Reports. Medicine|July 6, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish C Choudhary, et al.
Nature Biotechnology|April 28, 2022
Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variantsJason Z Zhang, Hsien-Wei Yeh, Alexandra C Walls, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Lineage-specific <i>tprK</i> diversification and <i>Treponema pallidum</i> transmission dynamics in Buenos Aires, ArgentinaNicole A P Lieberman, Luciana N Garcia, Shah A K Mohamed Bakhash, et al.
JAMA Network Open|April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical TrialsRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|April 24, 2024
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to RemdesivirKanal Singh, Kevin Rubenstein, Viviane Callier, et al.
Pageof 39